Cytori Therapeutics Inc. is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The company’s Celution System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets, but is not yet available in the US.
The company announced today that it has been issued Patent No. 4653952 from the Japan Patent Office covering devices for extracting and concentrating the stem and regenerative cells which naturally exist within adipose tissue. Specifically, the patent covers the underlying technology for Cytori’s Celution System family of devices, including the Celution 800 series and the next-generation Celution One series of devices, as well as the StemSource laboratory equipment.
This patent is the company’s first to be issued in Japan and will serve as Cytori’s foundational patent. Cytori already has ongoing strategic and commercial interests as it formed a joint venture with Olympus Corporation in 2005. Importantly for Cytori, the patent creates a significant barrier to entry for competitors through at least 2022 in the world’s second largest medical market.
Cytori now has 30 issued patents worldwide. These include 11 issued patents in the United States as well as issued patents in China, Singapore and South Korea. In addition, the company has more than 100 pending patent applications worldwide. For further information about Cytori Therapeutics, please visit the company’s website at www.cytori.com